Changes in concentration of cisplatin in perfusate and blood plasma in patients with peritoneal carcinomatosis during hyperthermic intraperitoneal chemoperfusion (hipec) using minimal extracorporeal circuit
N.N. Petrov Research Institute of Oncology
S.M. Kirov Military Medical Academy
Concentration of cisplatin in the perfusate and blood plasma in patients with peritoneal carcinomatosis during hyperthermic intraperitoneal chemoperfusion (HIPEC) using different techniques was measured by means of mass-spectrometry. In the control group (5 patients) HIPEC was performed in accordance with common technique using roller pump, in the study group (5 patients) HIPEC was performed by means of minimal extracorporeal circuit (mecc) using centrifugal pump and shorter perfusion lines. In the control group of patients concentration of cisplatin by the end of HIPEC was 46.2% of the total dose of the drug (200 mg), in the study group this value was 70.8%. In turn concentration of cisplatin in blood plasma of patients in the control group increased during HIPEC from 2.16% to 2.96% of the total dose of the drug while in the study group of patients concentration of cisplatin in blood plasma during HIPEC was raising from 2.17 to 2.38% of the total dose of cisplatin. Therefore in patients with peritoneal carcinomatosis it was shown that HIPEC using mecc has a significant pharmacokinetic advantage over commonly used technique of HIPEC.
2. Gyseinov K.D., Belyaev A.M., Senchik K.U. i dr. Gipertermicheskaya intraperitonealnaya himioterapiya (HIPEC) v lechenii recidivov raka yaichnika. Vopr onkol 2014; 60: 3: 343–347
3. Timofeeva E.S. Izolirovannaya himioperfyziya legkogo v kombinirovannom lechenii metastaticheskogo porajeniya legkih: Dis. na soiskanie ychenoi stepeni kand. med. nayk. Sankt-Peterbyrg 2011: 178 s.
4. Berreder J., Glehen O., Habre J. et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: a multiinstitutional study of 246 patients. J Clin Oncol 2009; 27: №15, Suppl.: 5542
5. De Bree E., Tsiftsis D.D. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: From laboratory bench to bedside. Recent Results Cancer Res 2007; 169: 53–73
6. Fujiwara K., Nagao S., Aotani E. Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer. Expert Opin Pharmacother 2013; 14: 13: 1797−1806
7. González-Moreno S., González-Bayón L.A., Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol 2010; 2: 2: 68–75
8. Losa F., Barrios P., Salazar R. et al. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin. Trans. Oncol. 2013. http://link.springer.com/article/10.1007%2Fs12094-013-1053-x
9. Lu Z., Wang J., Guilaume Wientjes M., Au J. Intraperitoneal therapy for peritoneal cancer. Future Oncol 2010; 6: 10: 1625–1641
10. Nissan A. Evidence-Based Medicine in the Treatment of Peritoneal Carcinomatosis: Past, Present, and Future. J Surg Oncol 2009; 100: 335–344.
11. Valtonen M., Vahasilta T., Kaila-Keinanen T., Kutilla K. New mini-extracorporeal circulation system (ECC.O) is a safe technique in coronary surgery. Scand Cardiovasc J 2007; 45: 1: 345–350
12. Witkamp A.M., de Bree E., Van Goethem A.R., Zoetmulder A.N. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer treatment reviews 2001; 27: 365–374